125 related articles for article (PubMed ID: 5015915)
1. Immunological effects of BCG in malignant melanoma: two modes of administration compared.
Bluming AZ; Vogel CL; Ziegler JL; Mody N; Kamya G
Ann Intern Med; 1972 Mar; 76(3):405-11. PubMed ID: 5015915
[No Abstract] [Full Text] [Related]
2. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
[No Abstract] [Full Text] [Related]
3. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
4. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
Nathanson L; Clark DA
Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
[No Abstract] [Full Text] [Related]
5. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
6. The immune response in human malignant melanoma.
Mackie RM
Clin Exp Dermatol; 1976 Mar; 1(1):23-8. PubMed ID: 773575
[No Abstract] [Full Text] [Related]
7. Immunotherapy of melanoma with intralesional BCG.
Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
[No Abstract] [Full Text] [Related]
8. Immunological changes in cancer patients receiving BCG.
Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
[TBL] [Abstract][Full Text] [Related]
9. [Immunoreactivity in patients with surgically removed melanoma in the course of BCG vaccination (author's transl)].
Lochman I; Kyselá T; Machálek J; Lochmanová A; Beska F
Cesk Dermatol; 1980; 55(6):372-7. PubMed ID: 7460040
[No Abstract] [Full Text] [Related]
10. Histologic changes in the human skin melanoma after intratumorous treatment with BCG.
Svejda J; Mechl Z; Sopková B; Foukal T
Neoplasma; 1979; 26(2):215-21. PubMed ID: 471128
[TBL] [Abstract][Full Text] [Related]
11. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
12. The use of oral BCG in the treatment or metastatic malignant melanoma.
Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of human malignant melanoma with oil-attached BCG cell-wall skeleton.
Yamamura Y; Yoshizaki K; Azuma I; Yagura T; Watanabe T
Gan; 1975 Aug; 66(4):355-63. PubMed ID: 1102379
[TBL] [Abstract][Full Text] [Related]
14. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
[No Abstract] [Full Text] [Related]
15. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
16. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
[No Abstract] [Full Text] [Related]
17. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
Seigler HF; Shingleton WW; Pickrell KL
Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
[TBL] [Abstract][Full Text] [Related]
18. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.
Cassel WA; Murray DR; Torbin AH; Olkowski ZL; Moore ME
Cancer; 1977 Aug; 40(2):672-9. PubMed ID: 196739
[TBL] [Abstract][Full Text] [Related]
19. Results of administering B.C.G. to patients with melanoma.
Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
[No Abstract] [Full Text] [Related]
20. [Multidisciplinary treatment of malignant melanoma of the nose and paranasal sinuses--with special reference to oral administration of enterosoluble BCG capsules].
Saito H; Hozawa J; Takagi A; Fukuoka K; Nozawa I; Kamimura T
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1555-61. PubMed ID: 6191718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
